NCT06422247
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
Bristol-Myers Squibb·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Peripheral T-cell Lymphoma
- Drug/Device/Intervention
- Systemic therapy
- Study type
- Observational
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Bristol-Myers Squibb
- Location
- Minato-ku, Japan
Timeline & enrollment
- Phase
- N/A
- Start date
- Jun 14, 2024
- End date
- Apr 30, 2025
- Enrollment
- 300 participants
Primary outcome
Overall survival (OS)
Summary
The purpose of this study is to describe the therapeutic practices and the prognosis of
 patients with relapsed or refractory peripheral T-cell lymphoma in Japan
ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06422247
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06422247 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.